Biocon has confirmed that the company’s Fulphila (pegfilgrastimjmdb) biosimilar has been launched by partner Mylan in the US, at a 33% discount to reference product Neulasta’s wholesale acquisition cost (WAC).
Biocon confirms US Neulasta rival launch
Biocon has confirmed that the company’s Fulphila (pegfilgrastimjmdb) biosimilar has been launched by partner Mylan in the US, at a 33% discount to reference product Neulasta’s wholesale acquisition cost (WAC).
More from Archive
More from Generics Bulletin
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.
• By
Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.